Shenzhen Bioeasy Biotechnology Co., Ltd. Class A

Shenzhen Bioeasy Biotechnology Co., Ltd. Class A

SSZSE:300942
5.45
CNY
-0.12
(-2.15%)
-0.07EPS
2.69BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A carries a market capitalization of 2.69B, placing it among publicly traded companies globally. Its enterprise value stands at 2.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.69B
Enterprise Value2.61B

Share Statistics

As of September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A has 405.08M shares outstanding.

Shares Outstanding405.08M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 9.60, and the price-to-book ratio stands at 3.11.

PS Ratio9.60
PB Ratio3.11
P/TBV Ratio3.25

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 9.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.61B versus a market cap of 2.69B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales9.30

Financial Position

As of September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A maintains a current ratio of 7.45, meaning it holds 7.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 51.96, indicating elevated leverage, while an interest coverage ratio of -1.60 demonstrates limited ability to service its debt obligations.

Current Ratio7.45
Quick Ratio5.23
Debt / Equity51.96
Debt / EBITDA-10.37
Interest Coverage-1.60

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A posted a negative return on equity (ROE) of -3.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.20, reflecting losses generated across the asset base. The company generates approximately 517,885.80 in revenue per employee across its workforce of 542.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.73 indicates how many times Shenzhen Bioeasy Biotechnology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-3.66
Return on Assets (ROA)-2.20
Revenue Per Employee517,885.80
Employee Count542.00
Inventory Turnover1.73

Taxes

CNY

Over the twelve months ended September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A recorded an income tax benefit of -7.52M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -37.65M and -31.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-7.52M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A's stock has declined approximately 49.16% over the past 52 weeks. The 50-day moving average sits at 6.23, while the 200-day moving average is 7.35.

52-Week Price Change-49.16%
50-Day Moving Average6.23
200-Day Moving Average7.35

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A generated 280.69M in revenue and converted that into -31.68M in net income, yielding earnings per share of -0.07. EBITDA reached -43.74M, while operating income came in at 14.24M.

Revenue280.69M
Gross Profit169.58M
Operating Income14.24M
Pretax Income-37.65M
Net Income-31.68M
EBITDA-43.74M
EBIT-43.74M
Earnings Per Share (EPS)-0.07

Balance Sheet

CNY

As of September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A holds 544.11M in cash and equivalents against 453.39M in total debt, resulting in a net debt position of -37.55M. Total book value stands at 865.79M, with working capital of 671.10M providing operational flexibility.

Cash & Cash Equivalents544.11M
Total Debt453.39M
Net Debt-37.55M
Equity (Book Value)865.79M
Book Value Per Share2.14
Working Capital671.10M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-54.36M

Margins

Over the twelve months ended September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A posted a gross margin of 60.41, reflecting its pricing power and cost economics. The operating margin of 5.07 and net profit margin of -11.29 provide insight into operational efficiency.

Gross Margin60.41
Operating Margin5.07
Pretax Margin-13.41
Profit Margin-11.29
EBITDA Margin-15.58

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A paid dividends of 0.04 per share. The dividend payout ratio of -59.49 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.94, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shenzhen Bioeasy Biotechnology Co., Ltd. Class A shareholders.

Dividend Per Share0.04
Payout Ratio-59.49
Shareholder Yield0.94

Scores

As of September 30, 2026, Shenzhen Bioeasy Biotechnology Co., Ltd. Class A has an Altman Z-Score of 3.69, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.69